Evotec's Technical Bounce Collides With a Hard Truth: The Pipeline Has Yet to Pay
Published on 09/04/2026 at 03:12 | Editorial boerse-global.de
The charts are finally offering Evotec shareholders something they haven't seen in months: a reason to look at the screen without wincing. Since the start of September, the stock has shown tentative signs of stabilizing, with a bullish divergence in the relative strength index suggesting the selling pressure that defined the summer is finally abating. On Thursday, the shares closed at EUR 3.27, down 0.7 percent on the day — a modest pullback, but one that comes after a sharp bounce at the start of the week.
What makes this recovery notable is what it lacks. There have been no earnings releases, no analyst upgrades, no deal announcements. This is purely a technical move, a sharp contrast to the catalysts that drove previous swings in the stock — profit warnings, downgrades, and collaboration news. The bounce arrives with the shares trading barely a few percentage points above their 52-week low of EUR 3.14, hit on September 2.
A Stock Caught Between Two Narratives
The fragility of the current setup is hard to overstate. Evotec has shed roughly 40 percent of its value since the start of the year and 44 percent over the past twelve months, leaving investors desperate for a floor. But the technical stabilization does nothing to address the structural problems that pushed the stock to these levels in the first place.
Just over a week ago, Evotec confirmed its first-half results: second-quarter revenue fell 16.2 percent to EUR 143.5 million, with adjusted EBITDA at minus EUR 20.8 million. The company had already slashed its full-year 2026 guidance, now projecting revenue between EUR 570 million and EUR 610 million and adjusted EBITDA of minus EUR 70 million to minus EUR 105 million. Management blamed shifted revenue from partnership milestones and delayed strategic collaborations, pushing a substantial portion of expected 2026 revenue into the following year. At the half-year mark, Evotec held liquidity of EUR 465.6 million.
The restructuring program "Horizon," launched in March, aims to consolidate the company's global footprint from 19 sites to 10, targeting annual savings of roughly EUR 75 million by the end of 2027. This year is expected to deliver 20 to 30 percent of those savings — though the reorganization itself cost EUR 75 million in the first quarter, largely from headcount reductions and write-downs.
Should investors sell immediately? Or is it worth buying Evotec?
The Plectonic Question
Into this delicate balance steps a new research collaboration with Plectonic Biotech, announced to develop a novel T-cell engager approach against solid tumors. Evotec contributes its BiTco platform; Plectonic brings the LOGIBODY technology. For a company whose share price has been battered, the deal offers a reminder that its technology platforms still attract partners.
But investors have been here before. The critical question isn't whether the science is sound — it's whether partnerships like this will translate into meaningful milestone and licensing payments, or remain research-only arrangements with negligible cash-flow impact. Evotec's business model depends on converting platform technologies into commercially viable milestone structures. Without financial details on the Plectonic deal, it remains unclear whether this partnership becomes a revenue driver or simply another addition to a growing but financially vague partner landscape.
The market's skepticism is reflected in the numbers. A financial portal cut the average price target for Evotec to EUR 4.60 from EUR 5.67 in late August — a reduction of over a euro. While that was more than four weeks ago and shouldn't be read as current analyst opinion, it signals that expectations have been revised downward rather than upward. The stock now sits 57 percent below its 52-week high of EUR 7.75 from November 5, 2025 — a stark measure of how much confidence has eroded.
What Would Change the Narrative
The bull case rests on Evotec converting BiTco into a series of commercially viable collaborations. If the Plectonic partnership yields concrete preclinical progress in the coming quarters — progress that translates into milestone payments — it would demonstrate that Evotec's platforms remain attractive to partners despite the stock's struggles. That could also ease the strategic debate that has been dominated by cost-cutting and restructuring concerns.
The bear case is equally clear: early-stage research partnerships without financial substance risk being dismissed as PR exercises. If Evotec continues announcing collaborations without clear milestone structures, the pressure on the stock is likely to persist.
With an RSI of 38.5 and annualized 30-day volatility of 38 percent, the stock remains volatile and firmly in oversold territory. A sustainable bottom would require visible progress on Horizon's savings targets or tangible wins from new strategic partnerships.
The next major test comes with the third-quarter report. Investors will be watching closely whether the revenue and partnership shifts outlined this summer genuinely resolve into the coming year — or whether the July guidance cut was merely the opening chapter of a longer drought. Until Evotec provides financial details on the Plectonic deal or similar collaborations, the stock remains caught between pipeline hope and the sobering reality of a company still working to rebuild trust after a punishing year.
Ad
Evotec Stock: New Analysis - 4 September
Fresh Evotec information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
